# Scalp Cooling in MBC

> **NCT04986579** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Chemotherapy-induced Alopecia

## Interventions

- **DEVICE:** Paxman Scalp Cooling System
- **DRUG:** Eribulin
- **DRUG:** Sacituzumab govitecan
- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT04986579
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-07
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04986579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04986579, "Scalp Cooling in MBC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04986579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*